证券日报网讯12月4日，新华医疗（600587）在互动平台回答投资者提问时表示，股东人数信息请关注 公司定期报告。 ...

证券日报网讯12月4日，新华医疗（600587）在互动平台回答投资者提问时表示，四季度公司生产经营 整体延续了三季度经营改善、聚焦主业的态势，同时在智能化转型落地、核心业务拓展上呈现出更多积 极进展。 ...

Core Viewpoint - The company has received medical device registration certificates for two products, the surgical shadowless lamp and the thoracic and abdominal endoscope, which are expected to enhance its product offerings and competitive edge in the medical device market [1][6]. Group 1: Surgical Shadowless Lamp - Product Name: Surgical Shadowless Lamp [1] - Registration Number: Lu Xie Zhu Zheng 20252010721 [1] - Features: Ultra-thin butterfly design, high color rendering medical LED light source, multiple modes for clinical needs [2] - Applicable Scope: Designed for surgical lighting in medical institutions [1] - Approval Date: November 27, 2025 [1] - Validity Period: Until November 26, 2030 [1] - Market Context: 101 companies in the same industry have obtained similar product registration certificates [1]. Group 2: Thoracic and Abdominal Endoscope - Product Name: Thoracic and Abdominal Endoscope [8] - Registration Number: Lu Xie Zhu Zheng 20252060702 [8] - Features: Dual-mode confocal design, ultra-clear imaging, and durable sapphire lens [5] - Applicable Scope: Used for examination and observation in thoracic and abdominal surgeries [4] - Approval Date: November 19, 2025 [4] - Validity Period: Until November 18, 2030 [4] - Market Context: 13 companies in the same industry have obtained similar product registration certificates [4]. Group 3: Impact on Company Performance - The surgical shadowless lamp meets diverse clinical lighting needs, enriching the company's surgical product line [6] - The thoracic and abdominal endoscope complements the company's medical fluorescence endoscope imaging system and minimally invasive surgical instruments, enhancing its product variety and core competitiveness [6].

Group 1 - The company Xinhua Medical responded to investor inquiries on December 4, indicating that relevant information regarding Huajian Medical should be monitored through its announcements [2]

Core Viewpoint - Xinhua Medical has a high employee count compared to other medical device companies due to its comprehensive business layout and complete industry chain, operating across four major sectors: medical devices, pharmaceutical equipment, medical trade, and medical services [2] Company Summary - Xinhua Medical is not just a manufacturer of medical devices but has developed a diversified industrial structure that supports collaborative development across multiple sectors [2] - The company's business layout requires personnel support across various functions including production, research and development, sales, and services, leading to a higher total employee count compared to companies focused on a single niche [2]

（文章来源：证券日报） 证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，关于收购中帜生物项目的进展， 敬请关注公司后续公告。 ...

Core Viewpoint - The company emphasizes its commitment to addressing stock price volatility and enhancing its core competitiveness and intrinsic value through various strategic initiatives [1] Group 1: Company Strategy - The company is focused on optimizing its business layout to ensure sustainable development [1] - The company aims to strengthen technological innovation as a key driver for growth [1] - The company is working to improve operational efficiency to create greater value for shareholders [1]

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，股价波动受宏观经济、行业周 期、市场情绪等多重因素综合影响，短期走势未能完全反映公司内在价值。当前行业环境虽存挑战，但 公司始终聚焦主业、稳健经营，持续推进核心业务升级与产品布局。后续公司将严格依规做好信息披 露，加强与投资者沟通，积极做好市值管理。 （编辑 丛可心 袁冠琳） ...

（编辑 姚尧） 证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，新华医疗在信息披露过程中，严 格区分控股股东的法定权利与违规获取信息的边界。公司不存在违反《上市公司信息披露管理办法》的 情形。 ...

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，市值差异本质是市场对传统制造 业与创新科技企业的估值逻辑分化。公司重视市值管理，正积极通过控股股东增持、优化分红、完善治 理结构、实施股权激励等方式方法进行市值管理。 （编辑 姚尧） ...